ArticleContraception: X2020
A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen.
Article in Contraception: X, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The impact of progestogens on RAAS - a systematic review.BMC women's health · 2025Pooled it
- Safety and Efficacy of a 24-Cycle Administration of a Drospirenone-Only Pill in Japanese Women.The journal of obstetrics and gynaecology research · 2026Trial
- Efficacy and safety of drospirenone as a progestin-only pill in Japanese women: A phase III study.The journal of obstetrics and gynaecology research · 2025Trial
- Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial.BMC women's health · 2022Trial
- Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime.BMC women's health · 2020Trial
- Oral contraceptive-associated hypertension as an under-recognized contributor to secondary and apparent resistant hypertension: agent-specific blood pressure liability, RAAS testing pitfalls, and practical assessment.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Cardiovascular disease in women: traditional and sex-specific risk factors.European heart journal · 2026Review
- Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges.Current hypertension reports · 2026Review
- Sex Hormone Supplementation and Cardiovascular Disease Risk.Medicina (Kaunas, Lithuania) · 2026Review
- Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper.Global heart · 2026Review
- Use of progestin-only drospirenone-based pills in hyperandrogenic women with polycystic ovary syndrome.Archives of gynecology and obstetrics · 2025Observational
- Anamnesis Checklist for Informed Oral Contraceptive Choices: A Spanish Perspective.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Contraceptive Care in the Rheumatic Diseases: A Review.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2024Review
- Safety of Progestogen Hormonal Contraceptive Methods during Lactation: An Overview.Clinics and practice · 2024Review
- Association between the use of oral contraceptives and the occurrence of systemic hypertension: A systematic review with statistical comparison between randomized clinical trial interventions.European journal of obstetrics & gynecology and reproductive biology: X · 2024Review
- The benefits of estetrol addition to drospirenone for contraception.AJOG global reports · 2023Article
- Oral Contraceptive Pills and Hypertension: A Review of Current Evidence and Recommendations.Hypertension (Dallas, Tex. : 1979) · 2023Review
- Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview.Journal of clinical medicine · 2022Review
- New Contraception Update - Annovera, Phexxi, Slynd, and Twirla.Current obstetrics and gynecology reports · 2022Article
- Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.Geburtshilfe und Frauenheilkunde · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate contraceptive effectiveness and safety of oral drospirenone 4 mg 24/4-day regimen in the United States. STUDY
designWe performed a prospective, single-arm, multicenter phase 3 trial in sexually active women for up to thirteen 28-day treatment cycles. Primary outcome was the Pearl index, calculated using confirmed on-drug pregnancies and evaluable cycles in nonbreastfeeding women aged ≤ 35 years. We assessed adverse events (AEs), including hyperkalemia and venous thromboembolism.
resultsOf 1006 women who received at least one dose of drospirenone, 352 women (35.0%) completed the trial and 654 (65.0%) women discontinued before trial end. Most participants (92.2%) were ≤ 35 years; one third had a body mass index (BMI) ≥ 30 kg/m
conclusionDrospirenone 4 mg 24/4 regimen provides effective contraception with a good safety/tolerability profile in a broad group of women, including overweight or obese women. IMPLICATIONS: This new progestin-only contraceptive, drospirenone 4 mg in a 24/4 regimen, provides a contraceptive option for the majority of women regardless of blood pressure or BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.